Cargando…

Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization

Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, A. L., Miquel‐Clopés, A., Wegmann, U., Jones, E., Stentz, R., Telatin, A., Walker, N. J., Butcher, W. A., Brown, P. J., Holmes, S., Dennis, M. J., Williamson, E. D., Funnell, S. G. P., Stock, M., Carding, S. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514708/
https://www.ncbi.nlm.nih.gov/pubmed/30985006
http://dx.doi.org/10.1111/cei.13301
_version_ 1783417923665133568
author Carvalho, A. L.
Miquel‐Clopés, A.
Wegmann, U.
Jones, E.
Stentz, R.
Telatin, A.
Walker, N. J.
Butcher, W. A.
Brown, P. J.
Holmes, S.
Dennis, M. J.
Williamson, E. D.
Funnell, S. G. P.
Stock, M.
Carding, S. R.
author_facet Carvalho, A. L.
Miquel‐Clopés, A.
Wegmann, U.
Jones, E.
Stentz, R.
Telatin, A.
Walker, N. J.
Butcher, W. A.
Brown, P. J.
Holmes, S.
Dennis, M. J.
Williamson, E. D.
Funnell, S. G. P.
Stock, M.
Carding, S. R.
author_sort Carvalho, A. L.
collection PubMed
description Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here we describe the means of delivering biologically active plague vaccine antigens directly to mucosal sites of plague infection using highly stable microvesicles (outer membrane vesicles; OMVs) that are naturally produced by the abundant and harmless human commensal gut bacterium Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the outer membrane and LcrV (V antigen) in the lumen, for targeted delivery to the gastrointestinal (GI) and respiratory tracts in a non‐human primate (NHP) host. Our key findings were that Bt OMVs stably expresses F1 and V plague antigens, particularly the V antigen, in the correct, immunogenic form. When delivered intranasally V‐OMVs elicited substantive and specific immune and antibody responses, both in the serum [immunoglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this included the generation of serum antibodies able to kill plague bacteria. Our results also showed that Bt OMV‐based vaccines had many desirable characteristics, including: biosafety and an absence of any adverse effects, pathology or gross alteration of resident microbial communities (microbiotas); high stability and thermo‐tolerance; needle‐free delivery; intrinsic adjuvanticity; the ability to stimulate both humoral and cell‐mediated immune responses; and targeting of primary sites of plague infection.
format Online
Article
Text
id pubmed-6514708
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65147082019-05-21 Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization Carvalho, A. L. Miquel‐Clopés, A. Wegmann, U. Jones, E. Stentz, R. Telatin, A. Walker, N. J. Butcher, W. A. Brown, P. J. Holmes, S. Dennis, M. J. Williamson, E. D. Funnell, S. G. P. Stock, M. Carding, S. R. Clin Exp Immunol Editor's Choice Plague caused by the Gram‐negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here we describe the means of delivering biologically active plague vaccine antigens directly to mucosal sites of plague infection using highly stable microvesicles (outer membrane vesicles; OMVs) that are naturally produced by the abundant and harmless human commensal gut bacterium Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the outer membrane and LcrV (V antigen) in the lumen, for targeted delivery to the gastrointestinal (GI) and respiratory tracts in a non‐human primate (NHP) host. Our key findings were that Bt OMVs stably expresses F1 and V plague antigens, particularly the V antigen, in the correct, immunogenic form. When delivered intranasally V‐OMVs elicited substantive and specific immune and antibody responses, both in the serum [immunoglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this included the generation of serum antibodies able to kill plague bacteria. Our results also showed that Bt OMV‐based vaccines had many desirable characteristics, including: biosafety and an absence of any adverse effects, pathology or gross alteration of resident microbial communities (microbiotas); high stability and thermo‐tolerance; needle‐free delivery; intrinsic adjuvanticity; the ability to stimulate both humoral and cell‐mediated immune responses; and targeting of primary sites of plague infection. John Wiley and Sons Inc. 2019-04-15 2019-06 /pmc/articles/PMC6514708/ /pubmed/30985006 http://dx.doi.org/10.1111/cei.13301 Text en © 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editor's Choice
Carvalho, A. L.
Miquel‐Clopés, A.
Wegmann, U.
Jones, E.
Stentz, R.
Telatin, A.
Walker, N. J.
Butcher, W. A.
Brown, P. J.
Holmes, S.
Dennis, M. J.
Williamson, E. D.
Funnell, S. G. P.
Stock, M.
Carding, S. R.
Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title_full Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title_fullStr Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title_full_unstemmed Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title_short Use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
title_sort use of bioengineered human commensal gut bacteria‐derived microvesicles for mucosal plague vaccine delivery and immunization
topic Editor's Choice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514708/
https://www.ncbi.nlm.nih.gov/pubmed/30985006
http://dx.doi.org/10.1111/cei.13301
work_keys_str_mv AT carvalhoal useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT miquelclopesa useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT wegmannu useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT jonese useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT stentzr useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT telatina useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT walkernj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT butcherwa useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT brownpj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT holmess useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT dennismj useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT williamsoned useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT funnellsgp useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT stockm useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization
AT cardingsr useofbioengineeredhumancommensalgutbacteriaderivedmicrovesiclesformucosalplaguevaccinedeliveryandimmunization